Methods of using adipose derived stem cells to treat acute tubular necrosis
View Patent ↗Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.
1. A method for treating acute tubular necrosis (ATN) in a patient, comprising:
identifying a patient with ATN; and
providing to the patient's renal vasculature an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
2. The method of claim 1 , wherein said patient is human.
3. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.
4. The method of claim 1 , wherein the ATN is ischemic ATN.
5. The method of claim 1 , wherein the ATN is nephrotoxic ATN.
6. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient in a bolus.
7. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient in multiple doses.
8. The method of claim 1 , further comprising providing one or more additives to said patient or to said concentrated population of cells comprising adipose-derived stem cells.
9. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells further comprises an additive.
10. The method of claim 9 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, and an angiogenic factor.
11. The method of claim 9 , wherein said additive is selected from the group consisting of collagenase, trypsin, lipase, hyalurondiase, deokyribonuclease, Liberase H1, a tissue or cell re-aggregation inhibitor, and pepsin, or any combination thereof.
12. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the patient.
13. The method of claim 12 , wherein said concentrated population of cells comprising adipose-derived stem cells is grown in culture conditions that promote differentiation towards a renal phenotype.
14. The method of claim 12 , wherein said concentrated population of cells comprising adipose-derived stem cells is grown in culture conditions that promote differentiation towards an endothelial phenotype.
15. The method of claim 12 , wherein the cell culture is performed on a scaffold that can be placed on or within the patient.
16. The method of claim 15 , wherein the scaffold is resorbable in vivo.
17. A method for treating acute tubular necrosis (ATN) in a patient, comprising:
identifying a patient with ATN; and
providing to the patient's renal parenchyma an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
18. The method of claim 17 , wherein said patient is human.
19. The method of claim 17 , wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.
20. The method of claim 17 , wherein the ATN is ischemic ATN.
21. The method of claim 17 , wherein the ATN is nephrotoxic ATN.
22. The method of claim 17 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient in a bolus.
23. The method of claim 17 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said patient in multiple doses.
24. The method of claim 17 , further comprising providing one or more additives to said patient or to said concentrated population of cells comprising adipose-derived stem cells.
25. The method of claim 17 , wherein said concentrated population of cells comprising adipose-derived stem cells further comprises an additive.
26. The method of claim 24 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, and an angiogenic factor.
27. The method of claim 25 , wherein said additive is selected from the group consisting of collagenase, trypsin, lipase, hyalurondiase, deoxyribonuclease, Liberase H1, a tissue or cell re-aggregation inhibitor, and pepsin, or any combination thereof.
28. The method of claim 18 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the patient.
29. The method of claim 28 , wherein said concentrated population of cells comprising adipose-derived stem cells is grown in culture conditions that promote differentiation towards a renal phenotype.
30. The method of claim 28 , wherein said concentrated population of cells comprising adipose-derived stem cells is grown in culture conditions that promote differentiation towards an endothelial phenotype.
31. The method of claim 28 , wherein the cell culture is performed on a scaffold that can be placed on or within the patient.
32. The method of claim 31 , wherein the scaffold is resorbable in vivo.
33. A method for treating acute tubular necrosis (ATN) in a patient, comprising:
identifying a patient with ATN; and
contacting the patient's kidney with an amount of a concentrated population of cells comprising adipose-derived stem cells sufficient to restore blood flow to an ischemic region of the kidney of said patient.
34. The method of claim 33 , further comprising providing one or more additives to said patient or to said concentrated population of cells comprising adipose-derived stem cells.
35. The method of claim 33 , wherein said concentrated population of cells comprising adipose-derived stem cells further comprises an additive.
36. The method of claim 34 , wherein said additive is selected from the group consisting of a disaggre g ation agent, an immunosuppressive agent, and an angiogenic factor.
37. The method of claim 34 , wherein said additive is selected from the group consisting of collagenase, trypsin, lipase, hyalurondiase, deoxyribonuclease, Liberase H1, a tissue or cell re-aggregation inhibitor, and pepsin, or any combination thereof.
38. The method of claim 33 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the patient.
39. A method for treating acute tubular necrosis (ATN) in a patient, comprising:
identifying a patient with ATN; and
contacting the patient's kidney with an amount of a concentrated population of cells comprising adipose-derived stem cells that is sufficient to increase blood flow to an ischemic region of the kidney said patient, wherein said concentrated population of cells is obtained in a self-contained adipose-derived stem cell processing unit, comprising:
a tissue collecting container configured to receive and disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment; and wherein said cell collection container, further comprises a centrifuge that facilitates separation of the cells in a suspension; and
an outlet that is structured to permit concentrated stem cells to be aseptically removed from said self-contained adipose-derived stem cell processing unit.
40. The method of claim 39 , further comprising providing one or more additives to said patient or to said concentrated population of cells comprising adipose-derived stem cells.
41. The method of claim 39 , wherein said concentrated population of cells comprising adipose-derived stem cells further comprises an additive.
42. The method of claim 40 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, and an angiogenic factor.
43. The method of claim 40 , wherein said additive is selected from the group consisting of collagenase, trypsin, lipase, hyalurondiase, doxyribonuclease, Liberase H1, a tissue or cell re-aggregation inhibitor, and pepsin, or any combination thereof.
44. The method of claim 39 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to contacting the patient's kidney.